Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 22, 2021
Under the terms of the manufacturing services and supply agreement, Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.
Lead Product(s): Regdanvimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Regkirona
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
The final stage of human tests of the drug candidate, known as Regkirona or CT-P59, is being conducted in 13 countries, including Korea, the US, Spain and Romania, the firm added. The treatment has cleared an emergency use authorization in Korea in February.